Concord Drugs Reports Negative Financial Results for Quarter Ending December 2023
Concord Drugs, a microcap pharmaceutical company, has reported a negative performance in the quarter ending December 2023. The company's net sales, operating profit, operating profit margin, profit before tax, and earnings per share have all seen a decline, leading to a 'Sell' call by MarketsMojo. Investors and experts are advised to closely monitor the company's future performance.
Concord Drugs, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending December 2023. According to the report, the company has seen a negative performance with a score of -9, a significant decrease from the previous quarter's score of 1.
The net sales for the quarter were reported at Rs 12.78 crore, showing a decline of -5.54% compared to the same quarter last year. This indicates a negative trend in the company's sales in the near term. The operating profit (PBDIT) for the quarter was at its lowest in the last five quarters, standing at Rs 0.63 crore. This also reflects a negative trend in the company's operating profit.
The operating profit margin for the quarter was reported at 4.93%, the lowest in the last five quarters. This indicates a decline in the company's efficiency. The profit before tax less other income (PBT) for the quarter was also at its lowest in the last five quarters, standing at Rs -0.26 crore. This shows a negative trend in the company's PBT in the near term.
The earnings per share (EPS) for the quarter were reported at Rs -0.24, the lowest in the last five quarters. This indicates a decline in the company's profitability and lower earnings for shareholders. Based on these financial results, MarketsMOJO has given a 'Sell' call for Concord Drugs' stock.
Investors and experts are advised to carefully consider these financial results before making any investment decisions. The company's performance in the quarter ending December 2023 has been negative, and it is important to monitor its future performance closely.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
